FeaturedCNS

Psilocybin COMP360 (COMP006)

COMPASS Pathways

COMP006 Phase 3 hit primary endpoint February 2026 — two doses of 25mg vs 1mg showed -3.8 MADRS difference (p<0.001). Both COMP005 and COMP006 now positive. NDA filing planned Q4 2026. First classic psychedelic with consistent Phase 3 data.

Treatment-Resistant Depression

Linked Studies

NCT05711940PrimaryACTIVE_NOT_RECRUITINGPHASE3

Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD

Treatment Resistant DepressionUpdated Jan 2026

Loading comments…

Also Known As

Development codes

COMP360COMP006

Other names

psilocybin

Search all trials →Request coverage update